Research progress of drug-induced pyoderma gangrenosum

doi:10.3877/cma.j.issn.1673-9450.2023.05.015

Abstract

Abstract:

Drug-induced pyoderma gangrenosum is an extremely rare neutrophilic dermatoses with unclear pathophysiology, difficult diagnosis and non-uniform treatment protocol. However, drug-induced pyoderma gangrenosum is a rare adverse drug reaction that often causes great suffering to patients. In this article, the pathogenesis, pathological examination, clinical manifestations, diagnosis and differential diagnosis, and treatment options of drug-induced pyoderma gangrenosum were reviewed, with the aim of providing a reference for the diagnosis and treatment of drug-induced pyoderma gangrenosum in clinical practice.

Key words: Pyoderma gangrenosum, Neutrophil extracellular traps, Mechanism, Treatment

Meiqi Lu, Jie Zhao, Fei Shan, Xinglei Wang, Duyin Jiang. Research progress of drug-induced pyoderma gangrenosum[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(05): 447-450.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2023.05.015

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2023/V18/I05/447

References 40

[1]	Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses[J]. Br J Dermatol, 2018, 178(3): 595-602.
[2]	Filosa A, Filosa G. Neutrophilic dermatoses: a broad spectrum of disease[J]. G Ital Dermatol Venereol, 2018, 153(2): 265-272.
[3]	Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation[J]. Blood, 2019, 133(20): 2178-2185.
[4]	Ravindran M, Khan MA, Palaniyar N. Neutrophil extracellular trap formation: physiology, pathology, and pharmacology[J]. Biomolecules, 2019, 9(8): 365.
[5]	Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria[J]. Science, 2004, 303(5663): 1532-1535.
[6]	Lee KH, Kronbichler A, Park DD, et al. Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review[J]. Autoimmun Rev, 2017, 16(11): 1160-1173.
[7]	Mistry P, Carmona-Rivera C, Ombrello AK, et al. Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome[J]. Ann Rheum Dis, 2018, 77(12): 1825-1833.
[8]	Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum[J]. Br J Dermatol, 2017, 177(1): 72-83.
[9]	Poppensieker K, Otte DM, Schürmann B, et al. CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells[J]. Proc Natl Acad Sci U S A, 2012, 109(10): 3897-3902.
[10]	Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum[J]. Nat Rev Dis Primers, 2020, 6(1): 81.
[11]	Marzano AV, Ortega-Loayza AG, Heath M, et al. Mechanisms of inflammation in neutrophil-mediated skin diseases[J]. Front Immunol, 2019, 10: 1059.
[12]	Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review[J]. J Am Acad Dermatol, 2015, 73(4): 691-698.
[13]	Park S, Shin H, Lee DH, et al. Pyoderma gangrenosum mimicking necrotizing fasciitis on magnetic resonance imaging: a case report and literature review[J]. Am J Case Rep, 2022, 23: e931734.
[14]	George C, Deroide F, Rustin M. Pyoderma gangrenosum- a guide to diagnosis and management[J]. Clin Med (Lond), 2019, 19(3): 224-228.
[15]	Landis ET, Taheri A, Jorizzo JL. Gulliver′s sign: a recognizable transition from inflammatory to healing stages of pyoderma gangrenosum[J]. J Dermatolog Treat, 2015, 26(2): 171-172.
[16]	Jimenez-Cauhe J, Fonda-Pascual P. Visual dermatology: gulliver sign: when pyoderma gangrenosum soothes[J]. Journal of Cutaneous Medicine and Surgery, 2020, 24(4): 408.
[17]	李瑾，杨道秋，翟志芳，等. 坏疽性脓皮病28例临床分析[J]. 临床皮肤科杂志，2017, 46(4): 230-233.
[18]	冯尘尘，杨转花，李高洁，等. 坏疽性脓皮病诊疗研究进展[J]. 中国麻风皮肤病杂志，2022, 38(6): 414-418.
[19]	黎晓丽，林乃余，唐旭华，等. 坏疽性脓皮病发病机制的研究进展[J]. 皮肤性病诊疗学杂志，2022, 29(2): 178-181.
[20]	Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment[J]. Am J Clin Dermatol, 2017, 18(4): 555-562.
[21]	Garcovich S, Genovese G, Moltrasio C, et al. PASH, PAPASH, PsAPASH, and PASS: the autoinflammatory syndromes of hidradenitis suppurativa[J]. Clin Dermatol, 2021, 39(2): 240-247.
[22]	杨岚，杨青文，付妍婕. 坏疽性脓皮病发病机制与诊断的研究进展[J]. 中华烧伤与创面修复杂志，2022, 38(6): 569-573.
[23]	Su WPD, Davis MDP, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria[J]. Int J Dermatol, 2004, 43(11): 790-800.
[24]	杨海琼，彭琳琳，景东云，等. 误诊为坏疽性脓皮病的皮肤播散型孢子丝菌病1例[J]. 中国皮肤性病学杂志，2020, 34(1): 107-110.
[25]	冀斐，孟昭影. 坏疽性脓皮病2例并文献复习[J]. 中国中西医结合皮肤性病学杂志，2022, 21(6): 542-545.
[26]	杨枫，陈怡雯，侯麦花. 人工皮炎误诊为坏疽性脓皮病1例[J]. 中国皮肤性病学杂志，2018, 32(12): 1469-1471.
[27]	Wang JY, French LE, Shear NH, et al. Drug-induced pyoderma gangrenosum: a review[J]. Am J Clin Dermatol, 2018, 19(1): 67-77.
[28]	郑飞跃，吴燕，饶跃峰，等. 诺氏评估量表在药物不良反应评价中的作用及实例分析[J]. 中国药学杂志，2012, 47(8): 650-652.
[29]	Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment[J]. Expert Rev Clin Immunol, 2018, 14(3): 225-233.
[30]	曾琳茜，姚越，黄欣，等. 生物制剂在坏疽性脓皮病治疗中的研究进展[J/OL]. 中国皮肤性病学杂志( 2022-03-17 )[2023-07-15].
[31]	吴新果，黄茜，周小勇. 糖皮质激素联合环孢素A治疗溃疡型坏疽性脓皮病1例[J]. 中国皮肤性病学杂志，2015, 29(11): 1203, 1207.
[32]	陈红清. 嗜中性皮病的诊治进展[J]. 中国皮肤性病学杂志，2018, 32(10): 1213-1216.
[33]	Kolios AGA, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum[J]. Br J Dermatol, 2015, 173(5): 1216-1223.
[34]	Millet A, Pescarmona R, Belot A, et al. Quantification of canakinumab in human plasma by liquid chromatography-high resolution mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2022, 1211: 123475.
[35]	Burgdorf B, Schlott S, Ivanov IH, et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab[J]. Int Wound J, 2020, 17(4): 1086-1088.
[36]	Strunck JL, Cutler B, Latour E, et al. Wound care dressings for pyoderma gangrenosum[J]. J Am Acad Dermatol, 2022, 86(2): 458-460.
[37]	Chen B, Li W, Qu B. Practical aspects of the diagnosis and management of pyoderma gangrenosum[J]. Front Med (Lausanne), 2023, 10: 1134939.
[38]	Hao Y, He J, Zhao Z, et al. Clinical efficacy of flap transplantation combined with vacuum sealing drainage and methylprednisolone and cyclosporine in the treatment of pyoderma gangrenosum[J]. Int Wound J, 2023, 20(5): 1491-1497.
[39]	Goldust M, Hagstrom EL, Rathod D, et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J]. Expert Rev Clin Pharmacol, 2020, 13(2): 157-161.
[40]	Xia FD, Liu K, Lockwood S, et al. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis[J]. J Am Acad Dermatol, 2018, 78(2): 310-314.

Please choose a citation manager

Content to export